TrialClinical rheumatology2020

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Gerd Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.